Ambiq CEO sells 108K shares after option exercise
Ambiq Micro’s CEO exercised options for 117,771 shares and sold 108,500 shares in late August and early September 2026 under a Rule 10b5-1 plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ambiq Micro, Inc. (AMBQ) reports that Chief Executive Officer and director Fumihide Esaka exercised stock options covering 117,771 shares of common stock at exercise prices of $8.12 and $12.60 per share between August 31 and September 2, 2026. Over the same period, he sold 108,500 shares of common stock in a series of open-market transactions at weighted-average prices reported between $55.45 and $58.74 per share. The filing states these transactions occurred under a Rule 10b5-1 trading plan adopted on May 15, 2026.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
18 txns
Insider
Esaka Fumihide
Role
Chief Executive Officer
Sold
108,500 shs ($6.17M)
Approx. gross sale proceeds
$6.17M
Approx. exercise cost
$1.42M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F12 | 11,027 | $0.00 | $0.00 |
| Exercise | Common Stock | 11,027 | $12.60 | $139K |
| Sale | Common Stock F9 | 1,452 | $56.1529 | $82K |
| Sale | Common Stock F10 | 9,575 | $56.7701 | $544K |
| Exercise | Stock Option (Right to Buy) F12 | 48,973 | $0.00 | $0.00 |
| Exercise | Common Stock | 48,973 | $12.60 | $617K |
| Sale | Common Stock F8 | 48,973 | $56.3889 | $2.76M |
| Exercise | Stock Option (Right to Buy) F1, F11 | 13,500 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F12 | 35,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F13 | 9,271 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 13,500 | $8.12 | $110K |
| Sale | Common Stock F1, F2 | 5,899 | $56.866 | $335K |
| Sale | Common Stock F1, F3 | 5,501 | $57.7547 | $318K |
| Sale | Common Stock F1, F4 | 2,100 | $58.5186 | $123K |
| Exercise | Common Stock | 44,271 | $12.60 | $558K |
| Sale | Common Stock F5 | 15,600 | $56.8089 | $886K |
| Sale | Common Stock F6 | 13,800 | $57.7012 | $796K |
| Sale | Common Stock F7 | 5,600 | $58.4569 | $327K |
Holdings After Transaction:
Stock Option (Right to Buy) — 266,286 contracts (Direct);
Common Stock — 460,460 shares (Direct)
Footnotes (13)
- F1. The transactions occurred under a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026.
- F2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $56.35 to $57.34 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $57.37 to $58.24 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $58.42 to $58.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $56.29 to $57.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $57.29 to $58.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $58.29 to $58.49 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $56.00 to $56.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F9. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $55.45 to $56.44 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F10. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $56.46 to $57.06 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F11. 1/4 of the shares subject to the option vested on February 21, 2020, and 1/48 of the shares subject to the option vested in equal monthly installments thereafter, subject to the Reporting Person's continued service.
- F12. 1/48 of the shares subject to the option vested on June 26, 2021, and 1/48 of the shares subject to the option vested in equal monthly installments thereafter, subject to the Reporting Person's continued service.
- F13. 1/4 of the shares subject to the option vested on January 1, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Key Figures
Shares sold: 108,500 shares
Shares from option exercises: 117,771 shares
Option exercise price (lower grant): $8.12 per share
+4 more
7 metrics
Shares sold
108,500 shares
Total common shares sold by the CEO across reported transactions
Shares from option exercises
117,771 shares
Common shares underlying options exercised by the CEO
Option exercise price (lower grant)
$8.12 per share
Exercise price for one set of stock options exercised on August 31, 2026
Option exercise price (higher grants)
$12.60 per share
Exercise price for multiple option grants exercised on August 31, September 1, and September 2, 2026
Lowest disclosed sale range
$55.45 per share
Low end of the disclosed price range for one weighted-average sale on September 2, 2026
Highest disclosed sale range
$58.74 per share
High end of the disclosed price range for one weighted-average sale on August 31, 2026
Rule 10b5-1 plan adoption date
May 15, 2026
Date the CEO adopted the trading plan covering these transactions
Key Terms
Rule 10b5-1 plan, weighted average sale price, vested, equal monthly installments
4 terms
Rule 10b5-1 plan regulatory
"The transactions occurred under a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"The reported price in Column 4 is a weighted average sale price"
vested financial
"1/4 of the shares subject to the option vested on February 21, 2020"
equal monthly installments financial
"1/48 of the shares subject to the option vested in equal monthly installments thereafter"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider trading activity did AMBQ report for its CEO in this Form 4?
Ambiq Micro reported that CEO Fumihide Esaka exercised stock options for 117,771 shares of common stock and sold 108,500 shares in a series of open-market transactions between August 31 and September 2, 2026.
What were the option exercise prices in the AMBQ CEO’s Form 4?
The option exercises reported by Ambiq Micro’s CEO covered common shares at exercise prices of $8.12 and $12.60 per share, with expiration dates including February 20, 2029 and May 25, 2031.
Were the AMBQ CEO transactions made under a Rule 10b5-1 plan?
Yes. The filing states the transactions occurred under a Rule 10b5-1 plan adopted by the reporting person on May 15, 2026, indicating they were executed pursuant to a pre-arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
